Alterity Therapeutics Executes Conversion of 40,209 Options into Ordinary Shares at AUD 0.50 Each

Impact of Option Conversion on Alterity’s Share Capital Structure

Alterity Therapeutics Limited has completed the conversion of 40,209 options into ordinary fully paid shares after option holders exercised securities expiring on 31 August 2026. This transaction, finalized on 21 July 2026, reflects routine capital management where options were exercised at AUD 0.50 per share. The newly issued shares are now quoted on the ASX and hold equal rights with existing ordinary shares.

The exercise generated AUD 20,104.50 in gross cash consideration. Although modest, this conversion highlights ongoing participation by investors or employees in Alterity's capital structure through option-based incentive schemes. The shares issued carry the same rights and dividend entitlements as existing shares from the date of issue.

Alterity’s Updated Share Register Post-Conversion

Following this issuance, Alterity’s total ordinary fully paid shares quoted on the ASX stand at 217,629,367, reflecting cumulative conversions. This figure provides investors with a clear view of the company’s equity base and dilution potential as it advances its therapeutic pipeline.

In addition to ordinary shares, Alterity holds a complex portfolio of quoted and unquoted options. The quoted options include 18,504,224 expiring 31 August 2026 (the source of this conversion) and 24,446,043 expiring 26 February 2027. The unquoted options exceed 15 million across 14 series, with exercise prices ranging from USD 0.15 to AUD 1.875 and expiry dates extending to 15 June 2031. This layered capital structure supports employee incentives and equity financing strategies.

Outstanding Options and Potential for Future Share Issuances

Alterity’s extensive option portfolio presents ongoing potential for share conversions and dilution. The quoted options total approximately 42.9 million securities across two series, with the 31 August 2026 options now partially exercised. As expiry approaches, further conversions may occur if holders exercise their rights. The imminent expiry of the August 2026 series is a near-term catalyst, with remaining options set to expire shortly.

The unquoted options offer longer-term conversion opportunities over seven years. Key tranches include 4.2 million options exercisable at USD 0.302 expiring 15 April 2031, 6.2 million at USD 0.43 expiring 8 August 2030, and 3.4 million at AUD 0.50 expiring 30 December 2027. The mix of AUD and USD-denominated exercise prices indicates Alterity’s operations in both Australian and international markets, possibly linked to overseas partnerships or employee remuneration. Fully exercising the unquoted options could provide significant capital, subject to market conditions and holder decisions.

Overview of Alterity Therapeutics’ Business and Market Position

Alterity Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily in the research and development phase targeting rare neurological conditions with unmet needs. Listed on the ASX, Alterity funds its pipeline through capital raises, option conversions, and milestone payments. Its share and option structure aligns with typical early-stage biotech firms, using equity instruments for financing and employee incentives.

The reported conversion activity exemplifies Alterity’s capital management approach. Options enable capital raising at predetermined prices while incentivizing employees and advisors involved in drug development. The variety of exercise prices and expiry dates reflects multiple fundraising rounds, partnerships, and employment agreements over time.

Details on Cash Consideration and Exercise Pricing

The 40,209 options exercised on 21 July 2026 were priced at AUD 0.50 per share, a key historical capital raise level. This conversion generated AUD 20,104.50 in gross cash. The AUD 0.50 price point appears in other option series, including 300,000 unquoted options expiring 1 July 2030 and 3.4 million expiring 30 December 2027, indicating its significance in previous financing or incentive grants.

This pricing context helps investors evaluate Alterity’s valuation trends. The fact that option holders exercised at AUD 0.50 suggests the current share price exceeds this threshold, making conversion financially sensible. However, only a small portion of the 18.5 million quoted options were exercised, implying many holders may be awaiting further share price appreciation.

Compliance with ASX Quotation and Regulatory Requirements

Alterity’s application for quotation of the newly converted shares complies with ASX Listing Rules under Appendix 2A. Submitted on 21 July 2026, the application confirms these shares are additional securities within the existing ordinary fully paid share class, ensuring no new security class is introduced. This guarantees equal rights for new shares relative to existing ones.

The company stated that the new shares "will rank equally in all respects from their issue date with the existing issued securities in that class." This adherence to ASX rules ensures no shareholder is disadvantaged by the conversion. The shares became quoted securities effective 21 July 2026, allowing immediate trading. This process demonstrates Alterity’s commitment to transparency and continuous disclosure.

Capital Structure Insights for Alterity Investors

Investors should understand Alterity’s complex capital structure to assess dilution risks and capital availability. The combined 42.9 million quoted options and over 15 million unquoted options represent potential dilution if exercised. Exercise prices range from USD 0.15 to AUD 1.875, meaning conversions depend on share price relative to strike prices. Options below current share prices incentivize conversion, while others may expire unexercised.

The USD-denominated options introduce currency exposure, reflecting Alterity’s international operations, partnerships, or listings. The conversion update covers only a small fraction of total options, indicating substantial potential for future capital raises or dilution. Investors should monitor option expiry dates—especially the imminent 31 August 2026 expiry—to gauge conversion activity as share prices fluctuate.

Upcoming Capital Events and Dilution Outlook

The 31 August 2026 option expiry, with 40,209 shares converted, is a near-term milestone. Approximately 18.46 million remaining options in this series will either be exercised or expire worthless shortly. Conversion rates will depend on share price performance and holder sentiment. A share price rise above AUD 0.50 could trigger a significant conversion wave, adding millions of shares. Conversely, prices near or below the exercise price may lead holders to let options lapse.

Beyond August, further option expiries extend through June 2031, including 24.4 million quoted options expiring in February 2027. Each conversion event acts as a capital raise without formal placements or rights issues, making options a valuable funding mechanism. However, ongoing conversions also imply gradual dilution unless offset by share buybacks or other measures. Alterity has not provided guidance on managing dilution in this update.

Key Considerations for Investors Monitoring Alterity

Investors should focus on the outcome of the remaining 18.46 million options expiring 31 August 2026. Share price movements, clinical trial results, earnings updates, or partnership news ahead of expiry could influence conversion decisions. Accelerated conversions would indicate market confidence and provide additional capital, while minimal activity might reflect skepticism.

Longer term, investors should track Alterity’s progress in its therapeutic development pipeline. Regulatory milestones, clinical outcomes, and partnerships will more significantly impact shareholder value than option conversions alone. This conversion update represents routine capital management and should be considered alongside broader strategic developments reported in quarterly reports, financial statements, and corporate announcements.